We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-13.32%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.5B
AUM Growth
-$255M
Cap. Flow
+$290M
Cap. Flow %
11.6%
Top 10 Hldgs %
45.64%
Holding
89
New
6
Increased
32
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$50.9M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$35.6M
3
RLAY icon
Relay Therapeutics
RLAY
+$34M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$31.1M
5
ARGX icon
argenx
ARGX
+$29.1M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$50.6M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$29.4M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.95M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
1
GH Research
GHRS
$1.95B
$170M 6.79%
9,275,158
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.6B
$152M 6.07%
3,586,658
+406,000
+13% +$17.1M
RLAY icon
3
Relay Therapeutics
RLAY
$4.12B
$136M 5.42%
4,530,605
+1,400,000
+45% +$34M
RCUS icon
4
Arcus Biosciences
RCUS
$3.5B
$125M 5%
3,960,948
+562,881
+17% +$18.9M
MRUS
5
DELISTED
Merus
MRUS
$109M 4.37%
4,135,071
– –
ARGX icon
6
argenx
ARGX
$53.9B
$99.7M 3.99%
316,204
+100,000
+46% +$29.1M
PTGX icon
7
Protagonist Therapeutics
PTGX
$8.7B
$99.1M 3.96%
4,183,219
+531,460
+15% +$15M
XOMA
8
DELISTED
Xoma
XOMA
$98.8M 3.95%
3,530,543
– –
RPTX
9
DELISTED
Repare Therapeutics
RPTX
$83.4M 3.34%
5,858,776
+1,000,015
+21% +$14.8M
ACRS icon
10
Aclaris Therapeutics
ACRS
$728M
$68.6M 2.74%
3,976,543
+2,280,639
+134% +$31.1M
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.87B
$65.9M 2.64%
3,003,879
– –
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
$64.9M 2.6%
1,046,283
-110,110
-10% -$6.74M
CGEM icon
13
Cullinan Oncology
CGEM
$1.02B
$56.2M 2.25%
5,369,459
– –
KURA icon
14
Kura Oncology
KURA
$805M
$51.5M 2.06%
3,203,783
+1,139,571
+55% +$16.5M
EQRX
15
DELISTED
EQRx, Inc. Common Stock
EQRX
$49.7M 1.99%
12,025,570
+4,165,900
+53% +$18.1M
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.13B
$48.9M 1.95%
1,597,966
-1,691,574
-51% -$50.6M
RVMD icon
17
Revolution Medicines
RVMD
$39.9B
$46.2M 1.85%
1,810,549
– –
ITOS
18
DELISTED
iTeos Therapeutics
ITOS
$45.1M 1.8%
+1,400,201
New +$50.9M
RLMD icon
19
Relmada Therapeutics
RLMD
$533M
$44.5M 1.78%
1,647,400
– –
CTIC
20
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$41.7M 1.67%
8,929,690
– –
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.69B
$41.6M 1.66%
2,394,714
+295,000
+14% +$4.97M
FDMT icon
22
4D Molecular Therapeutics
FDMT
$539M
$40.3M 1.61%
2,664,521
+658,659
+33% +$10.3M
VRDN icon
23
Viridian Therapeutics
VRDN
$2.12B
$32.2M 1.29%
1,744,012
-135,400
-7% -$2.6M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1.02B
$31.6M 1.26%
7,411,503
– –
CINC
25
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$30.4M 1.22%
+1,735,293
New +$35.6M
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2022 Portfolio in Review

As of Q1 2022, BVF Inc held 89 positions worth $2.5B, down 9.3% from $2.76B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

BVF Inc deployed $290M of net new capital in Q1 2022, opening 6 new positions and adding to 32 existing holdings. Its largest new stake was iTeos Therapeutics: 1,400,201 shares worth $45.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $50.6M trimmed.

  • BVF Inc's largest Q1 2022 buy was iTeos Therapeutics: 1,400,201 shares worth $45.1M.
  • BVF Inc added most to Relay Therapeutics in Q1 2022, an estimated $34M increase.
  • BVF Inc's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $50.6M.
  • BVF Inc fully exited Amarin Corp in Q1 2022, selling an estimated $55.5M.
  • BVF Inc's ten largest holdings make up 46% of its $2.5B portfolio in Q1 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q1 2022.
  • BVF Inc's portfolio value fell 9.3% quarter-over-quarter to $2.5B.

Based on BVF Inc's 13F filing for Q1 2022, filed 16 May 2022.